Intramedullary pilocytic astrocytomas — a clinical and morphological study after combined surgical and photon or neutron therapy

Ten patients suffering from intramedullary pilocytic astrocytomas (WHO-classification: astrocytoma grade I) were investigated catamnesticly. Combined surgery and radiotherapy was performed. Seven patients received neutron irradiation postoperatively. In four cases the neurological symptoms were improved after follow-up periods ranging from 33 to 89 months. The three other patients died after 6 to 21 months. The autopsy findings of a 14 year old child are presented. Our results are compared with reports in the literature. In addition, long-term problems of the spinal column are discussed. It seems that the combined surgical and neutron therapy improves the prognosis of pencil gliomas.     

保留膀胱手术加膀胱内灌注疗法治疗膀胱癌的疗效观察

目的　总结保留膀胱手术治疗膀胱移行细胞癌的疗效和经验。方法　对接受保留膀胱手术并辅助膀胱内灌注治疗的 68例膀胱移行细胞癌患者做了回顾性分析。结果　平均随访时间 53 .5月 (5 - 83月 ) ,1 7例复发 ,8例进展 ,64例无瘤生存 ,3例死于膀胱癌 ,1例死于其它疾病。结论　表浅性和浅肌层浸润的膀胱癌可做保留膀胱的手术 ,而对于深肌层浸润的膀胱癌患者应尽早行膀胱全切术     

不同地区冬凌草有效成分抗肿瘤作用研究

卢氏1号及信阳A,B都是从冬凌草[Rabdosia rubescens(Hemsi)]中提取出来的,均为新的二萜类抗肿瘤成分,实验证明:这三种成分对体外培养的艾氏腹水癌细胞具有较明显的细胞毒作用。对动物移植性肿瘤ECA,ARS,S_(180),HCA,HCS,P_(388),L_(1210),LLC及B_(16)均有较强的抗肿瘤作用(P<0.05)。对小鼠体液免疫(溶皿素方法),及细胞免疫(肿瘤相伴免疫方法)均无明显影响。急性毒性LD_(50)卢氏1号为69.5±6.7mg/kg,信阳冬凌草水剂为10.6±0.9g/kgip。     

大蒜素对恶性肿瘤患者淋巴细胞免疫功能的影响

目的：探讨大蒜素对恶性肿瘤患者淋巴细胞免疫功能的影响。方法：恶性肿瘤患者每人每次口服大蒜素30mg,每日3次，连续服用，半年取其他化、放疗，用硷性磷酸酶－抗硷性磷酸酶（APAAP）法检测30例恶性肿瘤患者服用大蒜素前、后1、2、3月及30例正常对照组的淋巴细胞免疫功能。结果：恶性肿瘤患者淋巴细胞免疫功能显著低于对照组（P＜0．05），服用大蒜素后淋巴细胞免疫功能接近或高于对照组。结论：大蒜素能提高恶性肿瘤患者的淋巴细胞免疫功能。     

泌尿生殖系罕见病3例报告并文献复习

目的：探讨泌尿男生殖系罕见病的诊断与治疗方法。方法：回顾性分析3例精阜纤维上皮性息肉、先天性膀胱颈挛缩以及阴囊皮样囊肿患者的临床资料，术前采用排尿性膀胱尿道造影、膀胱尿道镜、尿动力学检查诊断；手术采用经尿道电切、钦激光内切开以及开放手术。结果：3例患者均于术前获得正确诊断，经手术治疗均得到满意疗效。结论：提高泌尿外科医生对罕见病的诊断及治疗水平十分重要。     

Infantile myofibromatosis

 Infantile myofibromatosis is a mesenchymal tumor most commonly seen in infancy. The tumors have a variable appearance on CT/MR and often simulate a more aggressive neoplasm. This report describes CT/MR findings in cases of infantile myofibromatosis with pathologic correlation. Discussion into the success of imaging in suggesting the correct diagnosis is also addressed. Infantile myofibromatosis is a mesenchymal disorder of infancy characterized by the presence of tumorous nodules in the skin, subcutaneous tissue, muscle, viscera, and bone. Cases of solitary and multiple lesions have been described. We present the clinical, histologic, and radiographic findings of one case of the solitary form of infantile myofibromatosis that was recently diagnosed at our hospital.     

Prophylaxis and treatment of bladder dysfunction after Wertheim-Meigs operation: the positive effect of early postoperative detrusor stimulation using the cholinergic drug betanecholchloride

The efficacy of betanecholchloride in the postoperative treatment of bladder dysfunction is controversial. We therefore performed a comparative study on the effect of this therapy for the prophylaxis of detrusor hypotonia after Wertheim-Meigs operation. Forty patients with cervical cancer FIGO stage Ib/IIa were divided into two study groups. The control group (24 patients) only received betanecholchloride if the residual urine persisted above 50 ml after the 10th postoperative day. The study group (16 patients) received 50 mg betanecholchloride three times a day from the 3rd postoperative day onward. In this group postoperative catheter treatment, and consequently hospital stay, were significantly shorter (9.6 versus 13.3 days and 15.5 versus 18.6 days). The residual urinary volume normalized faster (8.0 versus 13.0 days) and the rate of cystitis was lower (18.8 versus 25%). According to our study, a prophylactic application of the parasympathomimetic drug betanecholchloride diminishes postoperative complications associated with bladder dysfunction after Wertheim-Meigs operation. EDITORIAL COMMENT: Bladder dysfunction plays an important role after radical hysterectomy. The authors present data indicating improved and quicker resumption of bladder function following radical hysterectomy with early administration of betanecholchloride, versus use of the medication only when indicated by elevated postvoid residual. Although the study is not a double-blinded placebo-controlled trial, the patients who received beta-necholchloride from postoperative day 3 had significantly decreased postoperative catheter treatment, earlier resumption of adequate bladder emptying defined as a postvoid residual of less than 50 ml, decreased incidence of bladder infection and shorter hospital stay. This information is encouraging for this subset of patients, who characteristically are at high risk for long-term bladder dysfunction. Further studies in this area are needed to clarify therapeutic options to improve patients’ quality of life, specifically in regard to bladder function following treatment of their cancer.     

Expression of CD44V2 in transitional cell carcinoma of the urinary bladder and in urine

CD44 is the principal cell surface receptor for hyaluronate. Variant forms of the receptor, produced by alternative splicing, have been found to be associated with tumor progression in a variety of cancers. Based on investigations at the RNA level, it has recently been proposed that expression of CD44 variant V2 was present in urothelial cancer but not in normal urothelium. Since a distinctive marker for urothelial cancer would be extremely useful, frozen sections of normal urothelium and urothelial cancer were examined for expression of standard CD44 and CD44V2. Frozen sections of specimens of 35 patients with transitional cell carcinoma of the bladder, 16 specimens of normal bladder and 5 ureters were examined. Immunohistochemical staining was performed using a polyclonal antibody to CD44V2 (PAB CD44V2), a monoclonal antibody to CD44V2 (MAB CD44V2) and a monoclonal antibody to CD44S (MAB CD44S). CD44V2 and CD44S were also measured in lysates of urine sediments from 21 patients by enzyme-linked immunoabsorbent assay (ELISA). All investigated transitional cell carcinomas expressed CD44V2. There was no differentiation between invasive and noninvasive carcinoma. CD44V2 was also expressed in normal urothelium. Standard CD44 was expressed by the transitional cell carcinoma, normal urothelium, musculature and interstitial tissue. The amount of CD44V2 and CD44S in lysates of urine sediments is not correlated to diagnosis. In contrast to investigations at the RNA level, CD44V2 on the protein level seems not to be a distinctive marker for urothelial cancer. Therefore, CD44V2 will not be a useful diagnostic marker for detection of transitional cell carcinoma.     

Cytology of transitional-cell carcinoma of the urinary bladder: diagnostic yield and histologic basis.

The diagnostic yield of cytology in histologically proven transitional-cell carcinoma (TCC) of the urinary bladder has been studied in 100 cases. Cytohistologic correlation rates were 20 percent, 61.7 percent, and 92.8 percent, respectively, for grade 1, 2, and 3 tumors. When further evaluated, G2 cases were segregated into 2 subcategories, G2a and G2b, based on histologic preservation of nuclear polarity, pleomorphism, and other cellular irregularities. Correlation rates were rather low for G2a cases (6/18, 33%) and high for G2b cases, (23/29; 79%). The prevalence of atypical cells was 2 (11.1%) cases in G2a and 16 (55.2%) cases in G2b. The results of this study confirm that cytology has an extremely varying diagnostic yield in urinary bladder TCC. Greater cell exfoliation, increased atypia, and a tendency to infiltration of G2b and G3 cases probably account for the higher diagnostic yield detected in these groups.     

Inhibition by indomethacin of spontaneous mammary tumorigenesis in SHN mice

This experiment was designed to examine the effects of indomethacin, a potent prostaglandin synthesis inhibitor, on spontaneous mammary tumors in mice. The growth of established mammary tumors and the appearance of new tumors in multiparous SHN mice were significantly suppressed by the subcutaneous implantation of pellets of indomethacin diluted to 1/12 with cholesterol. Furthermore, the same treatment inhibited normal and preneoplastic mammary gland growth in virgin SHN mice. The pattern of estrous cycles, ovarian structure, and plasma prolactin levels were not affected significantly by the treatment. All results have demonstrated that indomethacin inhibits mammary tumorigenesis of mice primarily by route(s) other than the endocrine system under the present experimental conditions. Indomethacin would be the first agent that appears to inhibit the growth of spontaneous mammary tumors of palpable size in mice.